EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis

被引:128
作者
Crea, Francesco [1 ]
Fornaro, Lorenzo [2 ,3 ]
Bocci, Guido [1 ,4 ]
Sun, Lei [5 ]
Farrar, William L. [5 ]
Falcone, Alfredo [2 ]
Danesi, Romano [1 ]
机构
[1] Univ Pisa, Div Pharmacol, Dept Internal Med, I-56126 Pisa, Italy
[2] Univ Pisa, Div Med Oncol Transplants & New Technol Med, Dept Oncol, I-56126 Pisa, Italy
[3] Scuola Super Studi Univ & Perfezionamento St Anna, Inst Life Sci, I-56127 Pisa, Italy
[4] Ist Toscano Tumori, I-50139 Florence, Italy
[5] Frederick Natl Lab Canc Res, Canc Stem Cell Sect, Lab Canc Prevent, Frederick, MD USA
关键词
EZH2; Metastasis; Angiogenesis; DZNeP; Polycomb; HISTONE METHYLTRANSFERASE EZH2; GENE-EXPRESSION; NEOADJUVANT CHEMOTHERAPY; MESENCHYMAL TRANSITION; ANTITUMOR-ACTIVITY; STEM-CELLS; CANCER; POLYCOMB; BEVACIZUMAB; METASTASIS;
D O I
10.1007/s10555-012-9387-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor angiogenesis and metastatic spreading are two highly interconnected phenomena, which contribute to cancer-associated deaths. Thus, the identification of novel strategies to target angiogenesis and metastatic spreading is crucial. Polycomb genes are a set of epigenetic effectors, structured in multimeric repressive complexes. EZH2 is the catalytic subunit of Polycomb repressive complex 2 (PRC2), which methylates histone H3 lysine 27, thereby silencing several tumor-suppressor genes. EZH2 is essential for cancer stem cell self-renewal. Interestingly, cancer stem cells are thought to be the seeds of metastatic spreading and are able to differentiate into tumor-associated endothelial cells. Pre-clinical studies showed that EZH2 is able to silence several anti-metastatic genes ( e.g., E-cadherin and tissue inhibitors of metalloproteinases), thereby favoring cell invasion and anchorage-independent growth. In addition, EZH2 seems to play a crucial role in the regulation of tumor angiogenesis. High EZH2 expression predicts poor prognosis, high grade, and high stage in several cancer types. Recently, a small molecule inhibitor of PRC2 (DZNeP) demonstrated promising anti-tumor activity, both in vitro and in vivo. Interestingly, DZNeP was able to inhibit cancer cell invasion and tumor angiogenesis in prostate and brain cancers, respectively. At tumor-inhibiting doses, DZNeP is not harmful for non-transformed cells. In the present manuscript, we review current evidence supporting a role of EZH2 in metastatic spreading and tumor angiogenesis. Using Oncomine datasets, we show that DZNeP targets are specifically silenced in some metastatic cancers, and some of them may inhibit angiogenesis. Based on this evidence, we propose the development of EZH2 inhibitors as anti-angiogenic and anti-metastatic therapy.
引用
收藏
页码:753 / 761
页数:9
相关论文
共 50 条
[41]   USP7 stabilizes EZH2 and enhances cancer malignant progression [J].
Zheng, Nana ;
Chu, Man ;
Lin, Min ;
He, Youhua ;
Wang, Zhiwei .
AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (01) :299-+
[42]   Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion [J].
Lihong Shi ;
Qiangsheng Zhang ;
Shirui Zhu ;
Qing Tang ;
Xin Chen ;
Rui Lan ;
Ningyu Wang ;
Yongxia Zhu .
Molecular and Cellular Biochemistry, 2024, 479 :831-841
[43]   Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma [J].
Wang, Zhengshi ;
Dai, Jiaqi ;
Yan, Jie ;
Zhang, Yun ;
Yin, Zhiqiang .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (07) :4770-4778
[44]   The role of EZH1 and EZH2 in development and cancer [J].
Lee, Soo Hyun ;
Li, Yingying ;
Kim, Hanbyeol ;
Eum, Seounghyun ;
Park, Kyumin ;
Lee, Chul-Hwan .
BMB REPORTS, 2022, 55 (12) :595-601
[45]   Fatty acid metabolism and drug resistance to EZH2 inhibition [J].
Wang, Yemin .
EBIOMEDICINE, 2022, 77
[46]   The role of EZH2 in tumour progression [J].
Chang, C-J ;
Hung, M-C .
BRITISH JOURNAL OF CANCER, 2012, 106 (02) :243-247
[47]   MiR-137 regulates the proliferation and invasion of glioma cells through EZH2/Wnt/β-catenin signaling pathway [J].
Wang, Zong ;
Yuan, Jiangwei ;
Yang, Yang ;
Li, Li ;
Liu, Jidong ;
Wang, Ying .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (01) :385-392
[48]   Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells [J].
Hibino, S. ;
Saito, Y. ;
Muramatsu, T. ;
Otani, A. ;
Kasai, Y. ;
Kimura, M. ;
Saito, H. .
ONCOGENESIS, 2014, 3 :e104-e104
[49]   The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration [J].
Bae, Woo Kyun ;
Kang, Keunsoo ;
Yu, Ji Hoon ;
Yoo, Kyung Hyun ;
Factor, Valentina M. ;
Kaji, Kosuke ;
Matter, Matthias ;
Thorgeirsson, Snorri ;
Hennighausen, Lothar .
FASEB JOURNAL, 2015, 29 (05) :1653-1662
[50]   MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2 [J].
Zeng, Weihua ;
Zou, Guorong ;
Cao, Xiaolong ;
Li, Weizhan .
CANCER CELL INTERNATIONAL, 2020, 20 (01)